Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD
Primary Purpose
Obsessive Compulsive Disorder
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Gamma Ventral Capsulotomy
Sponsored by
About this trial
This is an interventional treatment trial for Obsessive Compulsive Disorder
Eligibility Criteria
Inclusion Criteria:
- OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of 45 or less.
- Persistence of severe symptoms and impairment for five or more years despite: 1. at least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram, escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior therapy (≥20 sessions of expert exposure and response prevention), and 3. augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and clonazepam.
- Age between 18 and 65 years.
- Able to understand and comply with instructions.
- Able to give fully informed, written consent in the judgment of the Consent Monitor.
- Either drug free or on a stable drug regimen for at least 6 weeks.
- Good general health.
- A family member or significant other is available and willing to communicate with the research team if the patient's clinical status worsens.
- The local referring psychiatrist is willing to provide ongoing care.
Exclusion Criteria:
- Current or past psychotic disorder.
- Full-scale IQ below 85.
- A clinical history of bipolar mood disorder.
- Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome.
- Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
- Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia.
- Current or unstably remitted substance abuse, dependence, or a positive urine toxicology screen.
- Pregnancy and women of childbearing age not using effective contraception.
- Unable to adhere to operational and administrative study requirements (in the investigators' judgment).
- Clinical history of severe personality disorder.
- Imminent risk of suicide (in the investigators' judgment).
Sites / Locations
- Butler Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Gamma Ventral Capsulotomy
Arm Description
Outcomes
Primary Outcome Measures
Yale-Brown Obsessive Compulsive Severity Scale
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01849809
Brief Title
Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD
Official Title
Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 1993 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Butler Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A research study of the effectiveness and safety of gamma knife ventral capsulotomy in patients with severe intractable obsessive-compulsive disorder (OCD).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obsessive Compulsive Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Open Label
Allocation
N/A
Enrollment
57 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gamma Ventral Capsulotomy
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Gamma Ventral Capsulotomy
Primary Outcome Measure Information:
Title
Yale-Brown Obsessive Compulsive Severity Scale
Time Frame
Baseline to 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
OCD, diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 30 and a Social and Occupational Functioning Assessment Scale (SOFAS) score of 45 or less.
Persistence of severe symptoms and impairment for five or more years despite: 1. at least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter inhibitor trials (fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram, escitalopram, or clomipramine) alone or in combination with, 2. adequate behavior therapy (≥20 sessions of expert exposure and response prevention), and 3. augmentation of one of the selective SRIs with clomipramine, a neuroleptic, and clonazepam.
Age between 18 and 65 years.
Able to understand and comply with instructions.
Able to give fully informed, written consent in the judgment of the Consent Monitor.
Either drug free or on a stable drug regimen for at least 6 weeks.
Good general health.
A family member or significant other is available and willing to communicate with the research team if the patient's clinical status worsens.
The local referring psychiatrist is willing to provide ongoing care.
Exclusion Criteria:
Current or past psychotic disorder.
Full-scale IQ below 85.
A clinical history of bipolar mood disorder.
Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome.
Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
Inability to undergo presurgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia.
Current or unstably remitted substance abuse, dependence, or a positive urine toxicology screen.
Pregnancy and women of childbearing age not using effective contraception.
Unable to adhere to operational and administrative study requirements (in the investigators' judgment).
Clinical history of severe personality disorder.
Imminent risk of suicide (in the investigators' judgment).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Rasmussen, MD
Organizational Affiliation
Butler Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Butler Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
29361268
Citation
Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin NC, Malloy PJ, Salloway SP, Strong DR, Eisen JL, Jenike MA, Rauch SL, Baer L, Lindquist C. Gamma Ventral Capsulotomy in Intractable Obsessive-Compulsive Disorder. Biol Psychiatry. 2018 Sep 1;84(5):355-364. doi: 10.1016/j.biopsych.2017.11.034. Epub 2017 Dec 15.
Results Reference
derived
Learn more about this trial
Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD
We'll reach out to this number within 24 hrs